Found 341 clinical trials
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
of INCB106385 when given as monotherapy or in combination with INCMGA00012 in participants with selected CD8 T-cell-positive advanced solid tumors including SCCHN, NSCLC, ovarian cancer, CRPC, TNBC
- 46 views
- 11 Jul, 2022
- 19 locations
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this study is to determine the safety, tolerability, efficacy, PK and pharmacodynamics of INCAGN01876 when given in combination with retifanlimab. The study will consist of 2 parts: a safety lead-in part (Part 1) followed by a dose expansion part (Part 2).
- 0 views
- 28 Oct, 2022
- 2 locations
Study of INCA 0186 in Subjects With Advanced Solid Tumors
preliminary efficacy of INCA00186 when given alone or in combination with INCB106385 and/or retifanlimab in participants with specific advanced solid tumors; squamous cell carcinoma of the head and neck
- 8 views
- 07 Oct, 2022
- 9 locations
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors
subjects with locally advanced or metastatic, relapsed or refractory head and neck squamous cell carcinoma (HNSCC), relapsed or refractory non-small cell lung cancer (NSCLC), and advanced clear cell renal
- 13 views
- 08 Jul, 2022
- 8 locations
First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors
locally advanced or metastatic, relapsed or refractory head and neck squamous cell carcinoma (HNSCC), relapsed or refractory non-small cell lung cancer (NSCLC), and advanced clear cell renal cell
- 78 views
- 04 Oct, 2022
- 8 locations
NBTXR3 With or Without Cetuximab in LA-HNSCC
in treatment-naïve, platinum-ineligible, elderly participants with LA-HNSCC.
- 0 views
- 19 Apr, 2022
- 3 locations
Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma
Pembrolizumab monotherapy and platinum-based chemotherapy in the combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have been widely
- 0 views
- 07 Oct, 2022
- 1 location
A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC
following postoperative radiotherapy or chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinomas (HNSCC).
- 0 views
- 15 Oct, 2021
- 2 locations
Induction Modified TPF Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of the study is to evaluate the efficacy and safety of induction mTPF chemotherapy followed by concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of the head
- 0 views
- 07 Oct, 2022
- 1 location
Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging (PIVOT)
Known risk factors inducing squamous cell carcinomas of the head and neck are tabacco and alcohol intake. However, the incidence of human papillomavirus (HPV) related oropharyngeal carcinomas is increasing. It is known that HPV+ and HPV- tumors have a different reaction to (chemo)radiotherapy. The exact mechanisms underlying these differences is …
- 1 views
- 23 Feb, 2022
- 1 location